 III. To evaluate the toxicities according to the National Comprehensive Cancer Network NCCN Common Terminology Criteria for Adverse Events CTCAE version v4.03 and tolerability of nivolumab and Y-90 in patients with advanced hepatocellular carcinoma IV. To determine the disease control rate DCR to the combination of nivolumab and Y-90 at 24 months from the start of nivolumab treatment. 